Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03909334 |
|
Recruitment Status :
Active, not recruiting
First Posted : April 10, 2019
Last Update Posted : April 30, 2024
|
Sponsor:
Xiuning Le
Collaborators:
M.D. Anderson Cancer Center
Eli Lilly and Company
Information provided by (Responsible Party):
Xiuning Le, Hoosier Cancer Research Network
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | May 2024 |
| Estimated Study Completion Date : | June 2024 |